PriceTargets.com logo

Oruka Therapeutics - ORKA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.17
  • Forecasted Upside: 43.70%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$30.04 As of 10/23/2024 11:58 AM ET
▼ -0.15 (-0.50%)

This chart shows the closing price for ORKA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oruka Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORKA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORKA

Analyst Price Target is $43.17
▲ +43.70% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Oruka Therapeutics in the last 3 months. The average price target is $43.17, with a high forecast of $49.00 and a low forecast of $40.00. The average price target represents a 43.70% upside from the last price of $30.04.

This chart shows the closing price for ORKA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Oruka Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2024
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2024

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/11/2024Stifel NicolausInitiated CoverageBuy$49.00
10/7/2024HC WainwrightInitiated CoverageBuy$45.00
9/17/2024Leerink PartnrsUpgradeStrong-Buy
9/17/2024Leerink PartnersInitiated CoverageOutperform$44.00
9/16/2024Lifesci CapitalInitiated CoverageOutperform$41.00
9/16/2024TD CowenInitiated CoverageBuy
9/13/2024Jefferies Financial GroupInitiated CoverageBuy$40.00
9/4/2024WedbushInitiated CoverageOutperform$40.00
9/3/2024WedbushUpgradeStrong-Buy
(Data available from 10/23/2019 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024

Current Sentiment

  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oruka Therapeutics logo
ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.
Read More

Today's Range

Now: $30.04
Low: $29.50
High: $30.04

50 Day Range

MA: N/A

52 Week Range

Now: $30.04
Low: $18.72
High: $53.88

Volume

15,067 shs

Average Volume

54,898 shs

Market Capitalization

$36.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Oruka Therapeutics?

The following equities research analysts have issued reports on Oruka Therapeutics in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Lifesci Capital, Stifel Nicolaus, TD Cowen, and Wedbush.
View the latest analyst ratings for ORKA.

What is the current price target for Oruka Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Oruka Therapeutics in the last year. Their average twelve-month price target is $43.17, suggesting a possible upside of 43.7%. Stifel Nicolaus has the highest price target set, predicting ORKA will reach $49.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $40.00 for Oruka Therapeutics in the next year.
View the latest price targets for ORKA.

What is the current consensus analyst rating for Oruka Therapeutics?

Oruka Therapeutics currently has 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ORKA will outperform the market and that investors should add to their positions of Oruka Therapeutics.
View the latest ratings for ORKA.

What other companies compete with Oruka Therapeutics?

Other companies that are similar to Oruka Therapeutics include VolitionRx, OncoCyte, Aspira Women's Health, Trinity Biotech and Biomerica. Learn More about companies similar to Oruka Therapeutics.

How do I contact Oruka Therapeutics' investor relations team?

Oruka Therapeutics' physical mailing address is 10170 CHURCH RANCH WAY SUITE 100, WESTMINSTER CO, 80021. The company's listed phone number is 720-940-2100 and its investor relations email address is [email protected]. The official website for Oruka Therapeutics is www.arcabio.com. Learn More about contacing Oruka Therapeutics investor relations.